Colorectal cancer, the abnormal growth of cancerous cells in the large intestine or the rectum, is one of the most common ...

A long-standing practice through which people hospitalized for blood cancer treatment are restricted to eating cooked foods ...

Rates of multiple myeloma (MM), the second most common blood cancer in the United States, are increasing and are twice as ...

- Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi ® /Minjuvi ®) and lenalidomide in addition to R-CHOP met its primary endpoint of progression-free survival (PFS) - ...

A cutting-edge therapy using base-edited immune cells is offering a major breakthrough for patients with one of the toughest forms of blood cancer, T-cell acute lymphoblastic leukaemia. By precisely ...

Treatment with an immune and cancer cell-targeting antibody therapy eradicates residual traces of the blood cell cancer multiple myeloma, according to interim results from a clinical trial conducted ...

Liquid biopsy is increasingly recognized as a promising tool for cancer detection and treatment monitoring, yet its effectiveness is often limited by the extremely low levels of tumor-derived DNA ...

Weight-loss drugs have “little or no effect” on reducing the risk of cancers related to obesity, according to a new study. More than 100 million Americans are living with obesity, and deaths from 13 ...

Despite previous excitement around a potential link between GLP-1 drugs and a reduced risk of cancer, new research suggests the popular medications “probably have little or no effect” on a person’s ...

A groundbreaking new treatment using genome-edited immune cells, developed by scientists at UCL (University College London) and Great Ormond Street Hospital (GOSH), has shown promising results in ...